R&D Directions’ Great Investigational Drugs of 2007 Included Avicena's Huntington's Disease Drug Candidate
The pharmaceutical magazine R&D Directions selected Avicena Group, Inc. (OTC: AVGOE)'s lead Huntington's disease drug candidate, HD-02, as one of the "100 Great Investigational Drugs of 2007" in the magazine’s March issue.
Huntington’s disease (HD) is a progressive neurodegenerative disease caused by a defective gene that is often inherited from parent to child, leading to a programmed deterioration of neurons in those parts of the brain that are responsible for controlling cognitive, emotional and motor functions.
HD-02 was included in the said list based on the drug candidate's potential to address a major medical need in a growing therapeutic area.
HD-02 is novel drug candidate for the treatment of Huntington's disease (HD) with orphan drug designation in the U.S.
In clinical studies, HD-02 has demonstrated the ability to significantly reduce levels of the Huntington's disease marker as well as to slow the rate of disease progression.Find more details from the full report.
Comment Preview